Animal models for obsessive-compulsive disorders

Current Neuropharmacology

Volumn 2, Issue 2, 2004, Pages 169-181

  Man, James ^a   Hudson, A L ^a   Ashton, D ^b   Nutt, D J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Animal models; Obsessive compulsive disorder

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ARGIPRESSIN; BENZODIAZEPINE DERIVATIVE; CLOMIPRAMINE; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROTRANSMITTER; NICOTINE; OLANZAPINE; QUINPIROLE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL MODEL; ANOREXIA NERVOSA; DERMATITIS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE MODEL; DOG; DOPAMINERGIC SYSTEM; EXON; GENE CASSETTE; GENE INSERTION; GENETIC MODEL; GENETIC PREDISPOSITION; HOX GENE; HYPERACTIVITY; KNOCKOUT MOUSE; NONHUMAN; NONSENSE MUTATION; OBSESSIVE COMPULSIVE DISORDER; PATHOPHYSIOLOGY; REVIEW; SEROTONINERGIC SYSTEM; SYMPTOMATOLOGY; WEIGHT REDUCTION;

EID: 3042697137     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570159043476792     Document Type: Review

References (92)

1. Alexander, G.E., Crutcher, M.D. (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. TINS, 13: 266-271.
2. Alsobrook, J.P. II, Leckman, J.F., Goodman, W.K., Rasmussen, S.A., Pauls, D.L. (1999) Segregation analysis of obsessive-compulsive disorder using symptom-based factor scores. Am. J. Med.Genet., 88, 669-675.
3. Altemus, M. Glowa, J.R., Gallivan, E., Leong, Y.M., Murphy, D.L. (1996) Effects of serotonergic agents on food-restriction-induced hyperactivity. Pharmacol. Biochem. Behav., 53, 123-31.
4. Altemus, M., Pigott, T., Kalogeras, K., Demitrack, M., Dubbert, B., Murphy, D., Gold. P. (1992) Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch. Gen. Psychiatry, 49, 9-20.
5. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders, 4th ed. Washington, USA: American Psychiatric Press.
6. Arnold, P.D., Richter, M.A. (2001). Is obsessive-compulsive disorder an autoimmune disease? CMAJ, 165 (10), 1353-1357.
7. Ballenger, J.C. (1999). Current treatments of the anxiety disorders in adults. Biological Psychiatry, 46, 1570-1594.
8. Baumgarten, H.G., Grozdanovic, Z. (1998). Role of serotonin in obsessive-compulsive disorder. British Journal of Psychiatry, 173 (suppl. 35), 13-20.
9. Baxter, L.R., Schwartz, J.M., Bergman, K.S., Szuba, M.P., Guze, B.H., Mazziotta, J.C., Alazraki.A., Selin, C.E., Ferng, H.K., Munford, P. et al. (1992) Caudate glucose metabolic rate changes with both drug and behaviour therapy for OCD. Arch. Gen. Psychiatry, 49, 681-689.
10. Bebbington, P.E. (1998) Epidemiology of obsessive-compulsive disorder. British Journal of Psychiatry, 173 (suppl. 38), 2-6.
11. Billett, E.A., Richter, Ma., Kennedy, J.L. (1998) Genetics of obsessive-compulsive disorder. In: Swinson, R.P., Antony, M.M., Rachman, S., Richter, M.A (eds), Obsessive-compulsive disorder, theory, research and treatment. New York: Guilford (pp. 181-206).
12. Black, D.W., Noyes, Jr. R., Goldstein, R.B., Blum, N. (1992) A family study of obsessive-compulsive disorder. Arch. Gen. Psychiatry, 49, 362-368.
13. Black, J.L., Geoff, T.L., Walikonis, J.E. (1998) Serologic survey of adult patients with obsessive-compulsive disorder for neuron-specific and other autoantibodies. Psychiatry Research, 81, 371-380.
14. Blier, P., de Montigny, C. (1999) Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology, 21, No. 2S.
15. Bogetto, F., Bellino, S., Vaschetto, P., Ziero, S. (2000) Olanzapine augmentation of fluoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Research, 96, 91-98.
16. Calvocoressi, L., Libman, D., Vegso, S.J., McDougle. C.J., Price, L.H. (1998) Global functioning of inpatients with obsessive compulsive disorder, schizophrenia, and major depression. Psychiatric Services, 49(3), 379-381.
17. Carey, G., Gottesman, II (1981) Twin and family studies of anxiety, phobic, and obsessive disorders. In: Klein Df, Rabkin JG (eds) Anxiety: new research and changing concepts. Raven Press, New York, pp 117-136.
18. Carlsson, M.L., Carlsson, A. (2000) Use of a nicotine receptor agonist in the treatment of obsessive compulsive disorder. Patent WO 00/25783 (pending).
19. Cavallini, M.C., Pasquale, L., Bellodi, L., Smeraldi, E. (1999) Complex segregation analysis of obsessive compulsive and spectrum disorders. Am. J. Med. Genet., 88, 38-43
20. Cheyette, S.R., Cummings, J.L. (1995) Encephalitis lethargica: lessons for contemporary neuropsychiatry. Journal of Neuropsychiatry & Clinical Neurosciences, 7 (2), 125-134.
21. Cryan, J.F., Markou, A., Lucki, I. (2002) Assessing antidepressant activity in rodents: recent developments and future needs. TIPS 23, No. 5: 238-245.
22. D'haenen, H., Andrews, J.S. (2000) Animal models of affective disorders. Neuroscience Research Communications, 26 (3), 289-298.
23. Delgado, P.L., Moreno, A., (1998) Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. British Journal Psychiatry, 173, (suppl. 35), 21-35.
24. Dodman, N.H., Moon-Faneli, A., Mertens, P.A., et al. (1997) Animal models of obsessive compulsive disorder. In: Hollander E, Stein DJ (eds). Obsessive Compulsive Disorders: Diagnosis, Etiology, Treatment. New York: Marcel Dekker (99-144).
25. DuPont, R.L., Rice, D.P., Shiraki, S., Rowland. C. (1994) Economic costs of obsessive-compulsive disorder. Unpublished.
26. Ebert, D. (1996) Therapy with selective serotonin reuptake inhibitors (SSRI). Indications, uses and risks. Fortschritte der Medizin, 114, 243-247.
27. Eichstedt, J.A., Arnold, S.L. (2001) Childhood-onset obsessive-compulsive disorder: a tic-related subtype of OCD? Clin. Psychol. Rev., 21, 137-157.
28. Einat, H., Szechtman, H. (1993) Perseveration without hyperlocomotion in a spontaneous alternation task in rats sensitised to the dopamine agonist quinpirole. Physiology & Behaviour, 57, 55-59.
29. Ellenbrook & Cools (1990) Animal models with construct validity for schizophrenia. Behavioural Pharmacology, 1 (6): 469-490.
30. Enoch, M.A., Greenberg, B.D., Murphy, D.L., Goldman, D. (2001) Sexually dimorphic relationship of a 5-HT2A promotor polymorphism with obsessive-compulsive disorder. Biological Psychiatry, 49 (4), 385-388.
31. Falk, J.R., Halmi, K.A., Tryon, W.W. (1985) Activity measures in anorexia nervosa. Arch. Gen. Psych., 42 (8), 811-814.
32. Fernandez-Guasti, A., Ulloa, R.E, Nicolini, H. (2003) Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder. Psychopharmacology, 166, 195-201.
33. Friedman, S., et. al (1993) Obsessive compulsive disorder in two black ethnic groups: incidence in an urban dermatology clinic. Journal of Anxiety Disorders, 7, 343-348.
34. Gainetdinov, R.R., Caron, M.G. (1999) Genetic models in pharmacology: present status and future. Pharmacological Research, 39 (6), 403-4.
35. Geller, P.A., Klier, C.M., Neugebauer, R. (2001) Anxiety disorders following miscarriage. J. Clin. Psychiatry, 62, 432-438.
36. Geyer, M.A., Markou, A. (1995) Animal models of psychiatric disorders. In Bloom, F.E., Kupfer, D.J. (eds) Psychopharmacology: The Fourth Generation of Progress. Raven Press (787-798).
37. Goodman, W.K., Kozak, M.J., Liebowitz, M., White, K.L. (1996) Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. International Clinical Psychopharmacology, 11, 21-29.
38. Goodman, W.K., McDougle, C.J., Price, L.H. (1992) Pharmacotherapy of obsessive-compulsive disorder. J. Clin. Psychiatry, 53, 29-37.
39. Grados, M., Scahill, L., Riddle, M.A. (1999) Pharmacotherapy in children and adolescents with obsessive-compulsive disorder. Child. Adolesc. Psychiatr. Clin. North Am., 8, 617-634.
40. Graybiel, A.M., Rauch, S.L. (2000) Towards a neurobiology of obsessive compulsive disorder. Neuron, 28 (2), 343-347.
41. Greer, J.M., Capecchi, M.R. (2002) Hoxb8 is required for normal grooming in mice. Neuron, 33, 23-34.
42. Greist, J.H., et al. (1995) Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double-blind, placebo-controlled trial. European Journal of Clinical Research, 7, 195-204.
43. Hemmings, S.M.J., Kinnear, C.J., Niehaus, D.J.H., Moolman-Smook, .J.C., Lochner, C., Knowles. J.A., Corfield, V.A., Stein, D.J. (2003) Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder. European Neuropsychopharmacology, 13, 93-98.
44. Henderson, J.G. Jr., Pollard, C.A. (1988) Three types of obsessive compulsive disorder in a community sample. J. Clin. Psychol., 44, 747-752.
45. Holland, H.C. (1974) Displacement activity as a form of abnormal behaviour in animals, in Beech HR (ed): Obsessional States. London, Methuen: 161-173.
46. Hollander, E., et al. (1998) Are OCD spectrum disorders different phenotypes of OCD? Paper presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, 1998.
47. ICD-10 (1994) : International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Geneva, Switzerland: World Health Organization.
48. Inouye, E. (1965) Similar and dissimilar manifestations of obsessive-compulsive neurosis in monozygotic twins. Am. J. Psych., 121, 1171-1175.
49. Jenike, M.A. (1998) Neurosurgical treatment of obsessive-compulsive disorder. Br. J. Psychiatry, 35 (suppl.), 79-90.
50. Karayiorgou, M., Sobin, C., Blundell, M.L., Galke, B.L., Malinova, L., Goldberg, P., Ott, J., Gogos, J.A. (1999) Family-based association studies support a sexually dimorphic effect of COMT and MAOA on a genetic susceptibility to obsessive-compulsive disorder. Biological Psychiatry, 45, 1178-1189.
51. Kaye, W., Weltzin, T., Hsu, L., Bulik, C. (1992) An open trial of fluoxetine in patients with anoxeria nervosa. J. Clin. Psychiatry, 52, 464-471.
52. Kennedy, B., Schwab, J.J. (1997) Utilization of medical specialists by anxiety disorder patients. Psychosomatics, 38, 109-112.
53. Koran, L.M., McElroy, S.L., Davidson, J.R., Rasmussen, S.A., Hollander, E., Jenike, M.A. (1996) Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. Journal of Clinical Psychopharmacology, 16, 121-129.
54. Marks, I. (1997) Behaviour therapy for obsessive compulsive disorder: a decade of progress. Can. J. Psychiatry, 42, 1021-1027.
55. McDougle, C.J., Epperson, C.N., Pelton, G.H., Wasylink, S., Price, L.H. (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Archive of General Psychiatry, 57, 794-801.
56. McGinney, W.T. Jr., Bunney, W.E. Jr. (1969) Animal model of depression. In: Review of evidence: implication for research. Arch. Gen. Psychiatry, 21, 240-248.
57. McGinnis, W., Krumlauf, R. (1992) Homeobox genes and axial patterning. Cell, 68, 282-302.
58. Nestadt, G., Lan, T., Samuels, J., Riddle, M., Bienvenu III, O.J., Liang, K.Y., Hoehn-Saric, R., Cullen, B., Grados, M., Beaty, T.H., Shugart, Y.Y. (2000) Complex segregation analysis provides compelling evidence for a major gene underlying obsessive-compulsive disorder and for heterogeneity by sex. Am. J. Hum. Genet., 67, 1611-1616.
59. Nicolini, H., Hanna, G., Baxter, L. Jr., Schwartz, J., Weissbacker, K., Spence, M.A. (1991) Segregation analysis of obsessive-compulsive and associated disorders: preliminary results. Ursus Medicus, 1, 25-28.
60. Nutt, D.J., Forshall, S., Bell, C., Rich, A., Sandford, J., Nash, J., Argyropoulos, S. (1999) Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. European Neuropsychopharmacology, 9 (suppl. 3), S81-S86.
61. Overall, K.L. (2000) Natural animal models of human psychiatric conditions: assessment of mechanism and validity. Prog. NeuroPsychopharmacol. & Biol. Psychiat., 24, 727-776.
62. Pato, M.T., Pato, C.N., Pauls, D.L. (2002) Recent findings in the genetics of OCD. J. Clin. Psychiatry, 63, (suppl. 6), 30-33.
63. Pato, M.T., Schindler, K.M., Pato, C.N. (2001) The genetics of obsessive-compulsive disorder. Current Psychiatry Reports, 3, 163-168.
64. Pauls, D.L., Alsobrook, J.P., Goodman, W., Rasmussen, S., Leckman, J.F. (1995) A family study of obsessive-compulsive disorder. Am. J. Psychiatry, 152, 76-84.
65. Perez, J., Tardito, D., Ravizza, L., Racagni, G., Mori, S., Maina, G. (2000) Altered cAMP-dependent protein kinase A in platelets of patients with obsessive-compulsive disorder. Am. J. Psychiatry, 157, 284-286.
66. Pigott, T.A. (1998) Obsessive-compulsive disorder: symptom overview and epidemiology. Bulletin of the Menninger Clinic, 62, A4-32.
67. Radomsky, A.S., Rachman, S. (1999) Memory bias in obsessive-compulsive disorder (OCD). Behav. Res. Ther., 37, 605-618.
68. Rapoport, J., Ryland, D., Kriete, M. (1992) Drug treatment of canine acral lick: An animal model of obsessive-compulsive disorder. Arch. Gen. Psychiatry, 49, 517-521.
69. Rasmussen, S.A. (1986) Obsessive-compulsive disorder in dermatologic practice. Journal of the American Academy of Dermatology, 13, 965-967.
70. Rasmussen, S.A., Eisen, J.L. (1992) The epidemiology and clinical features of obsessive-compulsive disorder. Psychiatric Clinics of North America, 15, 743-758.
71. Robinson, D., Wu, H., Munne, R.A., Ashtari, M., Alvir, J.M.J., Lerner, G. et al. (1995) Reduced caudate nucleus volume in obsessive-compulsive disorder. Archive General Psychiatry, 52, 393-398.
72. Rosenberg, D.R., Keshavan, M.S. (1998) Towards a neurodevelopmental model of obsessive-compulsive disorder. Biol. Psychiatry, 43, 623-640.
73. Rubenstein, C., Pigott, T., Altemus, M., L'Heureux, F., Gray, J., Murphy, D. (1993) High rates of comorbid OCD patients with bulimia nervosa. Eating Disorders, 1, 147-155.
74. Saxena, S., Brody, A.L., Schwartz, J.M., Baxter, L.R. (1998) Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. British Journal of Psychiatry, 173 (suppl. 38), 26-37.
75. Shiloh, R., Nutt, D., Weizman, A. (2000) Chapter 16.5 Obsessive-compulsive disorder. In Shiloh, R., Nutt, D., Weizman, A. Eds, Atlas of Psychiatric Pharmacotherapy. Martin Dunitz, pp. 189
76. Stein. (2001) Obsessive-compulsive disorder. Lancet 360: 397-405
77. Stein, D.J., Allen, A., Bobes, J. et al. (2000) Quality of life in obsessive compulsive disorder. CNS Spectrums, 5 (suppl), 37-39.
78. Stein, D.J., Dodman, N.H., Borchelt, P., Hollander, E. (1994) Behavioural disorders in veterinary practise: relevance to psychiatry. Compr. Psychiatry, 35, 275-85.
79. Summerfeldt, L., et al. (1997) Prevalence of particular obsessions and compulsions in a clinic sample. In: Swinson R, Anotny M, Rachman S, Richter M (eds.). OCD: Theory, Research, and Treatment. Guilford. New York, NY.:7-8.
80. Szechtman, H., Culver, K., Eilam, D. (1999) Role of dopamine systems in obsessive-compulsive disorders (OCD): implications from a novel psychostimulant-induced animal model. Polish Journal of Pharmacology, 51, 55-61.
81. Szechtman, H., Eckert, M.J., Tse, W.S., Boersma, J.T., Bonura, C.A., McClelland, J.Z., Culver, K.E., Eilam, D. (2001) Compulsive checking behavior of quinpirole-sensitised rats as an animal model of Obsessive-compulsive disorder (OCD): form and control. BMC Neuroscience, 2, 4.
82. Szechtman, H., Sulis, W., Eilam, D. (1998) Quinpirole induces compulsive checking behaviour in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav. Neurosci., 112, 1475-85.
83. Tizabi, Y., Copeland, R.L. Jr., Brus, R., Kostrzewa, R.M. (1999) Nicotine blocks quinpirole-induced behavior in rats: psychiatric implications. Psychopharmacology, 145, 433-441.
84. Tizabi, Y., Louis, V.A., Taylor, C.T., Waxman, D., Culver, K.E., Szechtman, H. (2002) Effect of nicotine on quinpirole-induced checking behavior in rats: Implications for Obsessive Compulsive Disorder. Biological Psychiatry, 51, 164-171.
85. Wagner, W. et al. (1995) Fluvoxamine: a review of global drug-drug interaction data. Clinical Pharmacokinetics, 29(suppl 1), 26-32.
86. Williams, K.E., Koran, L.M. (1997) Obsessive-compulsive disorder in pregnancy, the puerperium, and the premenstruum. J. Clin. Psychiatry, 58, 330-334.
87. Willner, P. (1984) The validity of animal models of depression. Psychopharmacology, 83, 1-16.
88. Winkelmann. G, et al. (1994) Zwangsst rung: Komorbiditit und Implikationen fur die Behandlung. Praxis der Klinischen Verhaltensmedizin und Rehabilitation.
89. Woods, A., Smith, C., Szwczak, M., Dunn, R.W., Cornfelt, M., Corbett, R. (1993) Selective serotonin re-uptake inhibitors decrease schedule-induced polydispsia in rats : a potential model for obsessive compulsive disorder. Psychopharmacology, 112, 195-8.
90. Woody, E., Szechtman, H. (2000) Hypnotic hallucinations: towards a biology of epistemology. Contemporary Hypnosis, 17, 4-14.
91. Yadin, E., Friedman, E., Bridger, W.H. (1991) Spontaneous alternation behaviour: an animal model for obsessive-compulsive disorder? Pharmacol. Biochem. Behav., 411, 311-5.
92. Zohar, J., Muelleer, E.A., Insel, T.R., Zohar-Kadouch, R.C., Murphy, D.L. (1987) Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch. Gen. Psychiatry, 44, 946-951.